Thirty-one patients with bidimensionally measurable hormone-refractory prostatic cancer received trimetrexate (TMTX). Serial values of prostate-specific antigen (PSA) and acid phosphatase (SAP) were correlated with response. Five patients (17%; 95% confidence interval, 3% to 30%) achieved a partial remission for a median of 3 months (range, 3 to 7.5 months Trends in marker changes were much more apparent. Several "decision rules" were evaluated for use of markers as indices of disease progression. A 50% increase from the patient's minimum value in either PSA or SAP on two successive determinations correlated with progression in 90% of cases in this trial. TMTX has modest activity in prostatic cancer, and further trials are not warranted. Biochemical markers do not uniformly reflect disease activity in hormonerefractory disease, and changes in biochemical markers must be interpreted cautiously when used as the sole end point to assess efficacy in clinical trials.
Thirty-one patients with bidimensionally measurable hormone-refractory prostatic cancer received trimetrexate (TMTX) . Serial values of prostate-specific antigen (PSA) and acid phosphatase (SAP) were correlated with response. Five patients (17%; 95% confidence interval, 3% to 30%) achieved a partial remission for a median of 3 months (range, 3 to 7.5 months). Marker levels showed large variations with no discernible patterns. Serial PSA and SAP in 19 patients with abnormal baseline values showed a correlation with measurable disease response in only 68% (13 of 19) and 47% (nine of 19) of patients, respectively. Values were then smoothed using an exploratory data analysis technique of running medians and averages.
IN PROSTATIC cancer, only 5% to 15% of patients with hormone-refractory disease present with bidimensionally measurable tumor masses.' Phase II trials require a clear end point of response to evaluate the effect of a study agent. For the majority of patients who have nonmeasurable bone only disease, reliable end points are lacking. Biologic markers in prostatic cancer include those that are tumor-specific-acid phos-Trends in marker changes were much more apparent. Several "decision rules" were evaluated for use of markers as indices of disease progression. A 50% increase from the patient's minimum value in either PSA or SAP on two successive determinations correlated with progression in 90% of cases in this trial. TMTX has modest activity in prostatic cancer, and further trials are not warranted. Biochemical markers do not uniformly reflect disease activity in hormonerefractory disease, and changes in biochemical markers must be interpreted cautiously when used as the sole end point to assess efficacy in clinical trials. phatase (SAP) and prostate-specific antigen (PSA)-and those that reflect secondary effects of the tumor on the host-alkaline phosphatase, osteocalcin, 2 or urinary excretion of hydroxyproline. 3 ' 4 The latter are notoriously misleading in providing reliable information regarding the clinical status of disease. The value of PSA to monitor responses in phase II trials has yet to be defined.
SAP elevations correlate with extent of disease, and changes-both increases and decreases-parallel disease status in patients with hormone-naive disease treated with androgen deprivation. In hormone-refractory disease, significant variations have been observed independent of therapy, 22 TMTX differs from methotrexate in that entry is not affected by the reduced folate transport system. 23 Further, it is not polyglutamated. Because TMTX is active in breast, head and neck, and non-small-cell lung cancer, 22 and methotrexate is active in prostatic cancer, 24 a study of TMTX in patients with hormone-refractory disease was initiated. A parallel investigation of serial changes in PSA and SAP in patients with bidimensionally measurable disease was also performed in the context of the clinical trial. The aim was to develop criteria for use of biochemical markers as end points of efficacy for clinical trials.
MATERIALS AND METHODS
Patients with hormone-resistant metastatic prostatic adenocarcinoma histologically confirmed by the Department of Pathology were considered. Entry requirements included a Karnofsky performance status (KPS) > 50, adequate hematologic status (WBC _ 3,000 cells per microliter, platelets >_ 200,000/pL), serum bilirubin !_ 1.5 mg/dL, creatinine 5 2.0 mg/dL, BUN s 30 mg/dL, creatinine clearance in excess of 50 mL/min/1.73 m' and bidimensionally measurable disease. Measurable disease included lymph nodes palpable by physical examination, pulmonary nodules, retroperitoneal and pelvic masses on computed tomographic (CT) scan, and masses found by transabdominal ultrasound of the liver. Palpable tumor masses were measured by the largest perpendicular diameters by two independent observers. Patients with myelophthesis, biopsy confirmed, were eligible if measurable disease was also present. All roentgenographic material was evaluated independently. To prevent a disease flare following discontinuation of hormonal therapy, all patients, except those who had undergone prior orcheictomy, were maintained on androgen-ablative medications, including corticosteroids. For those with a prior orchiectomy, all hormonal therapy except corticosteroids was discontinued prior to study entry.
Prior to entry, all patients had a complete history and physical examination. Laboratory evaluation included an automated blood and platelet count, twelve-channel screening profile, SAP, PSA (20 patients), and serum creatinine. Blood samples were drawn prior to rectal examination. SAP was assayed by a colorimetric method using sodium thymolphthalein monophosphate as substrate (upper limits of normal 0.6 U/mL). PSA was assayed using a monoclonal two-site immunoenzymatic (Tandem; Hybritech, San Diego, CA). Using this assay, 99% of healthy men have serum levels less than 4.0 ng/mL.
Radiographic examinations included a chest roentgenogram, and to evaluate for measurable disease, a CT scan of the abdomen and pelvis or transrectal ultrasound was performed. Evaluation of prostatic size was not considered acceptable for this study by either ultrasound, CT scan, or digital rectal examination. However, one patient had an enlarging biopsy-proven rectal mass following prostatectomy and radiation therapy assessed by transrectal ultrasound. Roentgenograms and scans were repeated at 6-to 8-week intervals when used to evaluate response of measurable disease. Radionuclide bone scans with roentgenographic evaluation of abnormal areas were also obtained as clinically indicated. Informed consent was required prior to initiation of therapy.
The starting dose of TMTX was 8 mg/m2 intravenously (IV) daily times 5 days. Cycles were repeated every 21 days. Automated blood and platelet counts were obtained 10 to 14 days after treatment, while PSA and SAP determinations were generally performed weekly. Toxicities were graded according to the National Cancer Institute (NCI) Common Toxicity Scale. Subsequent TMTX doses were escalated by 25% if only reversible grade 1 or less toxicity was observed. Doses were reduced by 50% if grade 3 or greater toxicity developed during a previous cycle. An adequate trial was defined as one cycle (5 days) of therapy for evaluation of toxicity or one cycle and 3 weeks of observation for evaluation of response.
Response in measurable disease parameters was evaluated every two cycles (6 to 8 weeks) using criteria as previously described. 26 In general, partial remission (PR) required a 50% decrease in the summed products of two or more diameters of measurable soft tissue lesions for a minimum of 1 month; stabilization (STAB) a less than 25% increase or increase in tumor size for a mininum of 3 months; and progression (PROG) a greater than 25% increase in tumor size. Patients who required radiation therapy for symptomatic bony metastases were considered to have PROG at the start of radiation therapy. SAP and PSA measurements were not used for the classification of response. Similarly, while bone scans were not used for classification in a PR or STAB category, they were used to document progression. This required the demonstration of new areas of uptake on the scan, not an increase in intensity or increase in area of a previously visualized lesion. Patients who required radiation therapy for symptomatic bony metastases or symptomatic neurologic dysfunction such as epidural spinal cord compromise were considered to have progressed at the start of radiation therapy. Duration of response was measured from the start of treatment until documentation of progression.
Statistical Methods
Since there were few responses and all patients eventually progressed, statistical methods were used to assess the relationship between serial values of PSA, SAP, and documentation of clinical progression. For each patient, serial PSA and SAP values were plotted over time. Because the raw data had an irregular pattern in many cases, the data were smoothed using an exploratory data analysis technique of running medians and averages by the MINITAB procedure 4253H. A minimum of seven values was required for smoothing. The purpose of smoothing was to visualize the overall pattern of the sequences of data points while removing some of the variability of values from one time point to the next.
Twenty patients had at least seven serial values of PSA and SAP that could be used to determine whether an increase in PSA and/or SAP values predicted tumor progression. Increases of 50% and 100% over baseline marker values for two successive values were sought. Similarly, increases of 50% and 100% for two successive values over the minimum of a marker up to that time were assessed. "Predictive value of positive" means the proportion of patients for whom the condition (50% or 100% increase for two successive values) was met, and progression was documented clinically.
RESULTS

Clinical Results
Thirty-one patients were entered (21 at MSKCC and 10 at UMCC). The clinical characteristics are listed in Table 1 . The measurable disease sites in the 20 patients for whom serial PSA and SAP determinations were evaluated are listed separately. For the overall group, the median age was 65 years (range, 55 to 75) and KPS 80% (range, 70 to 100). Seventy-one percent received prior radiation therapy and two additional patients had previous radioactive iodine (125I) implantation. All had progressed on prior hormonal therapy. Measurable sites were retroperitoneal nodes (14 patients), pelvic nodes (four), palpable nodes by physical examination (four), hepatic disease (four), lung (three), skin (one), and prostate (one). One patient had myelophthesis with concurrent measurable hepatic disease. Baseline biochemical values showed that 93% (27 of 29 patients) and 95% (19 of 20) had abnormalities in SAP and PSA, respectively.
The maximum dose was 8 mg/m2 in 11 patients, 10 mg/m 2 in 11, 12.5 mg/m 2 in four, 15 mg/m 2 in two, 19.5 mg/m2 in two, and 29 mg/m2 in one. Four patients required dose reductions, three on cycle 2 and one on cycle 3. The median number of cycles was three (range, two to 10). Toxicities are outlined in Table 2 and included granulocytopenia in 45% of patients (19%, grade 2; 26%, grade 3 or 4), nadir sepsis in 3%, mucositis in 26%, nausea and vomiting in 39%, and reversible hepatic dysfunction in 3%. 
Time
Five patients (17%; 95% confidence interval, 3% to 30%) achieved a PR in measurable disease sites for a median duration of 3 (range, 1 to 7.5) months, and four (13%) remained stable for a median of 4 (range, 3.5 to 6) months. Two showed regression in supraclavicular adenopathy for 1 and 2 months, respectively. The first progressed in bone and the second patient progressed with base of skull metastases. His supraclavicular disease did not recur until his death at 10 months. Two showed regression in retroperitoneal and pelvic adenopathy for 10 and 6 months, respectively, but progressed in bone. The fifth patient presented with thrombocytopenia secondary to biopsy-proven marrow infiltration and using an increase in PSA alone, SAP alone, or an increase in either PSA or SAP. As shown in Table 3 , using a 100% increase from the baseline value as the decision rule, a predictive value of 35% for PSA, 25% for SAP, and 45% for either marker was observed. Using a 50% increase from baseline, the predictive value increased slightly to 65% when either marker was used. Similar results were observed using an increase of 100% from the observed minimum value. However, if a 50% increase from the minimum value was used, the predictive value was 80% for PSA, 80% for SAP, and 90% if an increase in either PSA or SAP were used. Thus, an increase in either PSA or SAP of greater than 50% from the observed minimum value, appeared to be an index of "time to progression" in this clinical trial. The present study showed TMTX to have modest activity in hormone-refractory prostatic cancer. The observed response rate, 17% (95% confidence interval, 3% to 30%) is similar to that reported with methotrexate. 24 The limited clinical use makes further evaluation unwarranted. As with many chemotherapeutic agents, responses were seen in soft tissue lesions, and progression was first documented in bone in five of five responding patients despite continued response in soft tissue. While the frequency of evaluations, every 6 to 8 weeks, may have been too short an interval to document "response" by bone scan, it was not too short to document progression, defined as the appearance of new lesions.
This study shows the clinical heterogeneity of hormone-refractory prostatic cancer at different metastatic sites. Similar observations have been reported for hormone-naive disease in which response and time to progression were recorded separately. Comparing soft tissue and bone in a series of 50 patients treated with androgen ablation, complete and partial responses were observed in 84% versus 27%, and progression within 2 years noted in 12% versus 44%, respectively. 27 Clearly, bone metastases are rela-tively insensitive and require alternative treatment approaches. 28 The unique clinical manifestations of hormone-refractory prostatic cancer, in particular its unique predilection for bone, make the evaluation of chemotherapeutic agents complex. This in part explains the wide disparity in response rates for "standard" agents, and led some investigators to avoid using any specific criteria of response and assess only "time to progression" as clinical trial end points. 19 This, too, can be difficult with disease limited to osseous sites where bone radiographs are unreliable indicators, and meaningful changes in bone scans may not occur for many months. In some cases, an increase in intensity may represent improvement-the flare phenomenon-in others progression, and in others reflect technical differences in the scanning technique.1, In hormone-refractory disease, elevations occur in only 70% of cases, may be minimal, 16 ' 3 3 and not correlated with a response to chemotherapy. 8 ' 3 0 PSA is expressed independent of SAP, is specific for prostatic tissue, and levels do correlate with extent of disease. '3,15,16, 32 Elevations usually antedate changes in other clinical assessments of progression by as long as 12 months in patients with localized disease, 33 and changes parallel response to hormonal therapy.14,15,17,18 For both SAP and PSA, fluctuations may be independent of treatment. In one study, 27 of 32 (82%) patients showed SAP variations outside the coefficient of variation of the assay in a 24-hour interval with values ranging from -65% to +85% of the 24-hour mean value. 7 With PSA, variations from -72% to +190% were observed around the 24-hour mean value. 9 These variations may simply reflect the heterogeneity of hormone-refractory prostatic cancer cells. 34 The results of the current study were disappointing as correlations between biochemical response and measurable disease response were observed in only 49% and 67% of patients with abnormal baseline values for SAP and PSA, respectively. More data regarding a correlation between response in measurable disease sites and changes in PSA levels are needed. This information may determine whether PSA can be used as an end point for clinical trials in this disease.
The present study demonstrates disparate variations in hormone-refractory disease. Both markers should be monitored, but treatment cannot be based on these parameters alone. As noted by Hudson et al,1 4 treatment decisions should not be based on single assay results. Smoothing of serial values was helpful in visualizing trends in marker values, despite spontaneous fluctuations in levels, and may be an early index of disease progression. The decision rule of a 50% increase in the patient's minimum value of either PSA or SAP on two successive determinations as a marker of disease progression for patients with nonmeasurable disease requires prospective validation. At this point, it is unclear what the significance of an increase in PSA from 16 to 24 in comparison to an increase from 200 to 300 represents. The former may represent spontaneous fluctuations, while the latter can be more readily accepted as true progression of disease. A correlation with partial response was not possible in this study due to the low response rate to TMTX, although a discordance in regression of soft tissue disease and a decrease in biochemical markers was observed in three of five patients.
Maintenance of androgen suppression while on chemotherapy trials may be particularly important if these decision rules are considered. Although this patient population progressed on primary hormonal therapy, the tumor retains sensitivity to exogenous androgens, which can produce a significant flare. 3 5 , 36 Patients treated with estrogens as primary therapy frequently have testicular atrophy that reduces the chance of a significant increase in serum testosterone following discontinuation of therapy. However, with the more widespread use of gonadotropinreleasing hormone analogs, which do not produce testicular atrophy even after long-term administration, an increase in serum testosterone with an associated flare in symptoms can occur rapidly. Further, as response to "effective agents" is frequently not observed until 8 to 12 weeks after initiation of treatment, 38 a significant marker elevation may occur before a response can be observed. These elevations may be falsely inter-preted as treatment failure, and a potentially useful agent may not be properly evaluated.
TMTX has modest activity, and further testing is not justified. The major difficulty in evaluating response in prostatic cancer is the lack of effective agents. This may explain the wide variations in measured values, and poor correlations with "response." Perhaps agents that consistently produce a greater than 50% or 1-log decrease on two serial PSA determinations should be considered for further investigation. In this context, decision rules can be prospectively validated, and the clinical use of PSA and SAP in hormone-refractory disease be better defined.
